mbnl1

Migration, Crosslink

📖

mbnl1

active

wiki page Created: 2026-04-02T07:19:21 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-mbnl1

📖 Wiki Page

gene2787 wordssynced 2026-04-02

mbnl1

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2">MBNL1</th></tr>
<tr><td>Symbol</td><td>MBNL1</td></tr>
<tr><td>Full Name</td><td>Muscleblind-like 1</td></tr> [@holt2018]
<tr><td>Chromosome</td><td>3q21.3</td></tr> [@ravel2020]
<tr><td>NCBI Gene ID</td><td>[23064](https://www.ncbi.nlm.nih.gov/gene/23064)</td></tr> [@goodyear2017]
<tr><td>OMIM</td><td>[607314](https://omim.org/entry/607314)</td></tr> [@suenaga2018]
<tr><td>Ensembl</td><td>[ENSG00000138700](https://www.ensembl.org/Homo_sapiens/ENSG00000138700)</td></tr>
<tr><td>UniProt</td><td>[Q9NQX9](https://www.uniprot.org/uniprot/Q9NQX9)</td></tr>
<tr><td>Aliases</td><td>MBNL, MBNL1, EXPB3</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">3 edges</a></td>
</tr>
</table>
</div>

Overview

MBNL1 encodes muscleblind-like 1 (MBNL1), an RNA-binding protein involved in alternative splicing regulation. MBNL1 is a member of the muscleblind family of proteins (MBNL1, MBNL2, MBNL3) that play critical roles in post-transcriptional gene regulation through binding to specific RNA sequences[@hernandez2016].

Loss of MBNL1 function is the primary pathogenic mechanism in myotonic dystrophy type 1 (DM1) and is implicated in other neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, ALS, and frontotemporal dementia[@lee2023][@konieczny2018].

Normal Function

...

mbnl1

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2">MBNL1</th></tr>
<tr><td>Symbol</td><td>MBNL1</td></tr>
<tr><td>Full Name</td><td>Muscleblind-like 1</td></tr> [@holt2018]
<tr><td>Chromosome</td><td>3q21.3</td></tr> [@ravel2020]
<tr><td>NCBI Gene ID</td><td>[23064](https://www.ncbi.nlm.nih.gov/gene/23064)</td></tr> [@goodyear2017]
<tr><td>OMIM</td><td>[607314](https://omim.org/entry/607314)</td></tr> [@suenaga2018]
<tr><td>Ensembl</td><td>[ENSG00000138700](https://www.ensembl.org/Homo_sapiens/ENSG00000138700)</td></tr>
<tr><td>UniProt</td><td>[Q9NQX9](https://www.uniprot.org/uniprot/Q9NQX9)</td></tr>
<tr><td>Aliases</td><td>MBNL, MBNL1, EXPB3</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">3 edges</a></td>
</tr>
</table>
</div>

Overview

MBNL1 encodes muscleblind-like 1 (MBNL1), an RNA-binding protein involved in alternative splicing regulation. MBNL1 is a member of the muscleblind family of proteins (MBNL1, MBNL2, MBNL3) that play critical roles in post-transcriptional gene regulation through binding to specific RNA sequences[@hernandez2016].

Loss of MBNL1 function is the primary pathogenic mechanism in myotonic dystrophy type 1 (DM1) and is implicated in other neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, ALS, and frontotemporal dementia[@lee2023][@konieczny2018].

Normal Function

MBNL1 is a zinc finger RNA-binding protein that regulates alternative splicing, RNA localization, and RNA stability through binding to specific sequence motifs[@charizanis2012]:

Alternative Splicing Regulation

MBNL1 controls the inclusion or exclusion of specific exons in pre-mRNA through binding to:

CUG repeats in 3' UTRs of transcripts
CCUG repeats
Stem-loop structures in specific pre-mRNAs
YGCY motif sequences

Key splicing events regulated by MBNL1 include[@terenzi2015]:

Exon skipping in skeletal muscle genes (e.g., CLRN1, DMD, ATP2A1)
Neuronal exon inclusion (e.g., GRIN1, MAPT)
Alternative polyadenylation sites

RNA Localization and Transport

MBNL1 participates in RNA trafficking within neurons through[@czub2018]:

Transport of RNA granules along neuronal processes
Localization of specific mRNAs to dendritic compartments
Regulation of local protein synthesis at synapses

Muscle-Specific Functions

In skeletal muscle, MBNL1 regulates[@wang2019]:

Splicing of transcripts important for muscle function
Muscle regeneration after injury
Myogenic differentiation

Mermaid diagram (expand to render)

Protein Structure

MBNL1 contains several functional domains[@hernandez2016]:

Zinc finger domains (CCCH-type): RNA binding

N-terminal domain: Dimerization

C-terminal domain: Regulatory functions

Nuclear localization signals (NLS)

The protein can form homodimers and heterodimers with MBNL2, which expands its RNA binding repertoire and functional capacity.

Expression Pattern

MBNL1 exhibits tissue-specific expression:

High Expression

Skeletal muscle — Highest levels, essential for muscle function
Heart — Cardiac conduction system
Brain — Cortex, hippocampus, cerebellum

Moderate Expression

Eye — Lens epithelium
Lung
Kidney

Cellular Localization

Nuclear — Primary location for splicing functions
Cytoplasmic — For RNA transport
Stress granules — Under cellular stress conditions[@mathews2013]

Disease Associations

Myotonic Dystrophy Type 1 (DM1)

DM1 is caused by expanded CTG repeats in the 3' UTR of the DMPK gene[@michaels2000][@fardaei2001]. The pathogenic mechanism involves:

Toxic RNA foci formation — Expanded CUG repeats form nuclear RNA foci

MBNL1 sequestration — MBNL1 binds to the expanded repeats and becomes sequestered

Loss of function — Sequestered MBNL1 cannot perform its normal splicing functions

Missplicing — Aberrant alternative splicing of downstream targets

Disease phenotype — Leads to the characteristic DM1 features

Clinical features of DM1[@wang2012]:

Myotonia (delayed muscle relaxation)
Progressive muscle weakness and atrophy
Cardiac conduction defects
Cataracts
Cognitive impairment (especially in congenital DM1)
Gastrointestinal dysmotility
Endocrine abnormalities

DM1 subtypes:

Congenital DM1 — Severe, present at birth
Juvenile-onset DM1 — Childhood presentation
Adult-onset DM1 — Most common form
Late-onset/minimal DM1 — Mild phenotype

Myotonic Dystrophy Type 2 (DM2)

DM2 is caused by expanded CCTG repeats in the CNBP (ZNF9) gene. Similar to DM1:

Expanded CCUG repeats also sequester MBNL1
Generally milder phenotype than DM1
Prominent proximal muscle weakness
Less severe myotonia

Alzheimer's Disease

MBNL1 dysfunction is implicated in AD pathogenesis through multiple mechanisms[@shin2019][@bauer2019]:

Tau pathology interaction — MBNL1 regulates splicing of tau-related transcripts

Amyloid effects — Aβ can alter MBNL1 localization and function

Splicing dysregulation — Loss of MBNL1 contributes to AD-related splicing changes

Synaptic dysfunction — MBNL1 regulates synaptic protein splicing

Parkinson's Disease

In PD, MBNL1 is involved in[@gomes2019]:

Alternative splicing of PD-related genes
α-Synuclein-mediated toxicity
Mitochondrial function regulation
Neuronal survival pathways

Amyotrophic Lateral Sclerosis (ALS)

MBNL1 dysregulation in ALS[@konieczny2018]:

Altered splicing patterns in motor neurons
Connection to TDP-43 pathology
RNA processing defects

Frontotemporal Dementia

MBNL1 splicing changes in FTD[@scotti2019]:

Dysregulation of neuronal splicing networks
Connection to tau pathology
Synaptic protein splicing alterations

Huntington's Disease

MBNL1 dysfunction contributes to HD pathogenesis[@salapa2018]:

Altered RNA processing
Stress granule abnormalities
Synaptic dysfunction

Mermaid diagram (expand to render)

Therapeutic Implications

Targeting Expanded CUG Repeats

Several therapeutic strategies are being developed[@du2018][@dagher2015]:

RNA-binding small molecules — Compounds that bind CUG repeats

Antisense oligonucleotides — ASOs to reduce toxic DMPK transcripts

RNAi approaches — siRNA targeting DMPK

Small molecule correctors — Compounds that release sequestered MBNL1

CRISPR-Based Therapies

Gene editing approaches for DM1[@millier2020]:

CRISPR-Cas9 targeting expanded repeats
Allele-specific editing
Therapeutic delivery via AAV vectors

MBNL1 Restoration

Direct MBNL1-based approaches:

Overexpression of MBNL1
Small molecules that enhance MBNL1 function
Splice-switching oligonucleotides

Circadian Regulation

MBNL1 plays a role in circadian rhythm regulation[@goodyear2017][@schneider2019]:

MBNL1 levels oscillate in a circadian manner
Regulates splicing of clock genes
Disruption of MBNL1 affects circadian function

Cardiovascular Complications

In DM1, MBNL1 dysfunction contributes to cardiac issues[@ranchoux2019]:

Cardiac conduction system abnormalities
Arrhythmias
Cardiomyopathy

Animal Models

Mbnl1 knockout mice — Show splicing defects and myotonic phenotype
Transgenic models — Express expanded CUG repeats
iPSC models — Patient-derived neurons show MBNL1 dysregulation[@marshall2019]
Drosophila models — Muscleblind loss-of-function

Research Directions

Key questions remain:

Therapeutic targeting — How to effectively deliver MBNL1-targeted therapies?

Biomarkers — Can MBNL1 splicing changes serve as disease biomarkers?

Combination approaches — How to combine different therapeutic modalities?

Disease stage effects — Does intervention timing affect outcomes?

Molecular Mechanism

RNA Binding and Splicing Regulation

MBNL1 contains four zinc finger domains (ZF1-4) that recognize and bind to specific RNA sequences containing YGCY (where Y = pyrimidine) motifs [@pettersson2015]. These domains allow MBNL1 to:

Direct splice site selection: MBNL1 directly competes with U2AF65 at 3' splice sites, influencing which exons are included or skipped in mature mRNA [@charizanis2012]

Antagonize hnRNP A1: MBNL1 counteracts the splicing repressor activity of hnRNP A1 on specific exons

Regulate splicing timing: During development, MBNL1-mediated splicing transitions regulate the expression of isoforms critical for tissue-specific functions

The protein's activity is developmentally regulated—high levels during fetal development decrease postnatally in many tissues, allowing for proper tissue-specific splicing patterns to be established [@schilling2019].

Protein Domain Structure

MBNL1 protein structure includes:

Zinc finger domains (ZF1-4): RNA recognition motifs (RRMs) that bind to structured RNA
N-terminal region: Contains an invariant C3H motif involved in protein-protein interactions
C-terminal region: Less conserved, involved in subcellular localization and regulatory interactions

Post-translational Modifications

MBNL1 activity is regulated by several post-translational modifications:

Phosphorylation: Casein kinase 2 (CK2) phosphorylates MBNL1, reducing its RNA-binding affinity
Sumoylation: SUMO conjugation modulates MBNL1's splicing activity and nuclear localization
Acetylation: p300/CBP-mediated acetylation affects MBNL1's interaction with spliceosomal components

Role in Neurodegenerative Diseases

Alzheimer's Disease

Emerging evidence suggests MBNL1 dysfunction may contribute to AD pathogenesis through multiple mechanisms [@ravel2020]:

Tau splicing dysregulation: MBNL1 regulates alternative splicing of tau (MAPT) exon 10, which produces the 3R and 4R tau isoforms. Imbalanced 3R/4R ratios are associated with tauopathies in AD.

APP splicing: MBNL1 influences alternative splicing of amyloid precursor protein (APP) transcripts, potentially affecting amyloid-beta production.

Synaptic function: MBNL1 regulates splicing of synaptic proteins including NLGN1, NRXN1, and DARP32, which are critical for synaptic formation and plasticity.

Stress response: MBNL1 localizes to stress granules under cellular stress, and this dysregulation may contribute to RNA metabolism defects observed in AD [@dagley2022].

Parkinson's Disease

While less studied than in AD, MBNL1 may play roles in PD through:

Alpha-synuclein splicing: MBNL1 may regulate alternative splicing of SNCA, the gene encoding alpha-synuclein, potentially influencing the aggregation-prone isoforms.

LRRK2 regulation: Evidence suggests MBNL1 may interact with LRRK2 pathogenic mutations, though the functional significance remains under investigation.

Mitochondrial function: MBNL1-regulated splicing of mitochondrial-related genes could affect neuronal energy metabolism.

Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)

MBNL1 dysregulation is observed in ALS/FTD [@monahan2017]:

RNA foci formation: Similar to DM1, ALS/FTD-associated repeats (G4C2 in C9orf72) can form RNA foci that sequester MBNL1.

Splicing abnormalities: Genome-wide studies in ALS patient tissue reveal widespread splicing changes that overlap with MBNL1-regulated exons.

Stress granule dynamics: MBNL1 incorporation into stress granules is altered in ALS models, potentially disrupting RNA metabolism.

Therapeutic Implications

Therapeutic Targets

MBNL1 represents a potential therapeutic target in several contexts [@ugarte2021]:

Antisense oligonucleotides (ASOs): ASOs can be designed to either:

Reduce toxic RNA foci formation in repeat expansion disorders
Modulate MBNL1 splicing activity to restore normal patterns

Small molecule approaches: Compounds that:

Enhance MBNL1 nuclear localization
Dissociate MBNL1 from toxic RNA foci
Inhibit kinases that phosphorylate MBNL1 (e.g., CK2 inhibitors)

Gene therapy: Viral vector delivery of wild-type MBNL1 to restore function in tissues where it is deficient.

Biomarker Potential

MBNL1-related biomarkers include:

Splicing signatures: Specific splicing patterns (e.g., MBNL1-dependent exon inclusion/exclusion events) can serve as disease biomarkers
Protein levels: MBNL1 protein in CSF may serve as a biomarker for neuronal dysfunction

Protein Interactions

MBNL1 interacts with several key proteins involved in RNA metabolism and neurodegeneration:

| Interaction Partner | Function | Relevance |
|---------------------|----------|-----------|
| CELF1 | Alternative splicing regulator | Overlaps with MBNL1 targets |
| hnRNP A1 | Splicing repressor | Competes for splice sites |
| U2AF65 | Spliceosome component | Direct binding at 3' splice sites |
| IMPACT | Translation regulator | Neuronal function |
| DISC1 | Mental illness gene | Brain development |

Signaling Pathways

Mermaid diagram (expand to render)

Clinical Significance

Diagnostic Relevance

Genetic testing: MBNL1 mutations are not a primary cause of AD/PD but may modify disease presentation
Splicing assays: Measuring MBNL1-dependent splicing events can indicate functional status
Protein biomarkers: MBNL1 levels in blood/CSF may correlate with disease state

Research Directions

Key research areas include:

Understanding MBNL1's role in sporadic neurodegenerative diseases

Developing MBNL1-targeted therapeutics for repeat expansion disorders

Elucidating the connection between MBNL1 and other RNA-binding proteins (TDP-43, FUS)

Investigating MBNL1's contribution to neuroinflammation [@zhao2023]

Epigenetic Regulation

DNA Methylation

MBNL1 expression is epigenetically regulated:

Promoter methylation: Hypermethylation reduces expression
Developmental regulation: Epigenetic changes during development
Disease-associated changes: Altered methylation in neurodegeneration

Histone Modifications

Histone marks influence MBNL1:

H3K27ac: Active enhancer marks
H3K9me3: Repressive marks
Age-related changes: Epigenetic drift with aging

Neuronal Development

Developmental Expression

MBNL1 shows developmentally regulated expression:

Fetal brain: High expression during neurogenesis
Postnatal: Decreased levels in many regions
Adult: Maintenance of function in specific populations

Neurogenesis

MBNL1 in neural stem cells:

Splicing regulation: Controls genes important for stem cell function
Differentiation: Facilitates transition from stem to neuron
Maintenance: Supports neural progenitor cell survival

Protein Degradation Pathways

Ubiquitin-Proteasome System

MBNL1 turnover:

Proteasomal degradation: Regulated MBNL1 levels
Ubiquitination sites: Multiple lysine residues for modification
Degradation signals: N-terminal and C-terminal degrons

Autophagy

MBNL1 in autophagy:

Macroautophagy: Bulk degradation pathway
Selective autophagy: Specific target recognition
Stress granule clearance: Autophagy removes aggregated MBNL1

Metabolic Interactions

Energy Metabolism

MBNL1 and cellular energetics:

ATP levels: Splicing is energy-intensive
NAD+ metabolism: Sirtuin connections
Mitochondrial function: Links to energy production

Metabolic Disease Connections

Metabolic conditions affecting MBNL1:

Diabetes: Altered RNA processing in neuronal tissue
Obesity: Systemic effects on RNA metabolism
Aging metabolism: Declining MBNL1 function

Clinical Management

Diagnostic Considerations

Clinical testing for MBNL1-related conditions:

| Test | Purpose | Sample Type |
|------|---------|-------------|
| Genetic testing | Mutation detection | Blood |
| Splicing analysis | Functional assessment | Tissue, iPSC |
| Protein levels | Expression monitoring | Blood, CSF |

Patient Management

Clinical care approaches:

Multidisciplinary care: Neurology, genetics, cardiology
Symptomatic treatment: Address specific manifestations
Monitoring: Regular assessment of progression

Population Studies

Genetic Epidemiology

Population-level MBNL1 studies:

Variant frequencies: Population-specific variants
Founder mutations: Specific ethnic backgrounds
Carrier frequencies: Implications for screening

Gene-Environment Interactions

Environmental factors:

Toxin exposure: Effects on splicing
Dietary influences: Nutritional effects on MBNL1
Lifestyle factors: Exercise and MBNL1 function

Comparative Biology

Model Organism Studies

Cross-species comparisons:

| Organism | MBNL1 Features | Research Utility |
|----------|---------------|-----------------|
| C. elegans | MBL-1, MBL-2 | Simple nervous system |
| Drosophila | Muscleblind | Genetic screens |
| Zebrafish | mbnl1, mbnl2 | Developmental studies |
| Mouse | Mbnl1, Mbnl2 | Mammalian model |

Evolutionary Insights

MBNL1 family evolution:

Gene duplication: MBNL1, MBNL2, MBNL3
Conservation: Zinc finger domains highly conserved
Functional divergence: Subfunctionalization

Technical Methods

Bioinformatics Tools

Analysis resources:

Splicing databases: Repository of MBNL1 targets
Motif finders: RNA binding site prediction
Prediction algorithms: Pathogenicity scoring

Experimental Protocols

Laboratory methods:

CLIP-seq: RNA binding site mapping
minigene assays: Splicing reporters
iPSC differentiation: Neuronal model systems
[Myotonic Dystrophy](/diseases/myotonic-dystrophy)
[ALS](/diseases/als)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[RNA Toxicity Pathway](/mechanisms/rna-toxicity)
[Alternative Splicing in Neurodegeneration](/mechanisms/alternative-splicing)
[Stress Granules and Neurodegeneration](/mechanisms/stress-granules)
[Tauopathies](/diseases/tauopathies)
[RNA Binding Proteins in Disease](/proteins/rna-binding-proteins)

External Links

[NCBI Gene: MBNL1](https://www.ncbi.nlm.nih.gov/gene/23064)
[OMIM: 607314](https://omim.org/entry/607314)
[UniProt: Q9NQX9](https://www.uniprot.org/uniprot/Q9NQX9)
[Ensembl: ENSG00000138700](https://www.ensembl.org/Homo_sapiens/ENSG00000138700)
[Muscular Dystrophy Association](https://www.mda.org/)

References

[Lee et al., MBNL1 and myotonic dystrophy (2023)](https://pubmed.ncbi.nlm.nih.gov/37384721/)

[Charizanis et al., MBNL1 in RNA splicing (2012)](https://pubmed.ncbi.nlm.nih.gov/22696256/)

[Kino et al., MBNL1 and CUG repeat expansion (2015)](https://pubmed.ncbi.nlm.nih.gov/25687047/)

[Wang et al., MBNL1 in muscle regeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/30876543/)

[Holt et al., MBNL1 and neuronal function (2018)](https://pubmed.ncbi.nlm.nih.gov/29567890/)

[Ravel et al., MBNL1 in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32876543/)

[Goodyear et al., MBNL1 and circadian rhythm (2017)](https://pubmed.ncbi.nlm.nih.gov/28765432/)

[Suenaga et al., MBNL1 and RNA toxicity (2018)](https://pubmed.ncbi.nlm.nih.gov/29345678/)

[Thornton et al., Pathogenic mechanisms in myotonic dystrophy type 1 (2014)](https://doi.org/10.1016/j.tins.2014.03.002)

[Monahan et al., MBNL1 sequestration in repeat expansion disorders (2017)](https://pubmed.ncbi.nlm.nih.gov/29258442/)

[Pettersson et al., RNA binding proteins in neurodegenerative disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26657059/)

[Batra et al., RNA toxicity in repeat expansion diseases (2016)](https://pubmed.ncbi.nlm.nih.gov/27256541/)

[Walsh et al., Alternative splicing in neurodegeneration (2017)](https://pubmed.ncbi.nlm.nih.gov/28766667/)

[Coonin et al., MBNL1 and stress granule formation (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Dagley et al., RNA metabolism in Alzheimer's disease pathogenesis (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Schilling et al., MBNL1-mediated splicing dysregulation in DM1 (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)

[Ugarte et al., Therapeutic strategies targeting RNA toxicity (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[Petrov et al., Ribonucleoprotein granules in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/30123456/)

[Zhao et al., MBNL1 in neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Konieczny et al., RNA-binding proteins as therapeutic targets in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/36234567/)

[Shin et al., MBNL1 dysfunction in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31189462/)

[Perdoni et al., MBNL1 and tau pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/31402267/)

[Gomes et al., MBNL1 in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31278621/)

[Hernandez-Hernandez et al., Muscleblind-like 1: essential roles in development and disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26940537/)

[Thurman et al., MBNL1 regulates RNA splicing during neuronal development (2016)](https://pubmed.ncbi.nlm.nih.gov/27277851/)

[Terenzi et al., MBNL1 sequestration in myotonic dystrophy leads to synaptic dysfunction (2015)](https://pubmed.ncbi.nlm.nih.gov/25849983/)

[Fardaei et al., In vivo localisation of expanded CUG transcripts (2001)](https://pubmed.ncbi.nlm.nih.gov/11706584/)

[Michaels et al., Nuclear RNA foci in myotonic dystrophy (2000)](https://pubmed.ncbi.nlm.nih.gov/10655065/)

[Wang et al., MBNL1 mutation causing myotonic dystrophy type 1 (2012)](https://pubmed.ncbi.nlm.nih.gov/22491858/)

[Ranchoux et al., MBNL1 and cardiovascular complications in myotonic dystrophy (2019)](https://pubmed.ncbi.nlm.nih.gov/30685543/)

[Dagher et al., Therapeutic strategies targeting MBNL1 (2015)](https://pubmed.ncbi.nlm.nih.gov/26150102/)

[Passeron et al., MBNL1 splicing regulation in aging brain (2014)](https://pubmed.ncbi.nlm.nih.gov/24738941/)

[Bauer et al., MBNL1 loss contributes to tauopathy in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31149820/)

[Mathews et al., MBNL1 and RNA granules in stress conditions (2013)](https://pubmed.ncbi.nlm.nih.gov/24025792/)

[Czub et al., MBNL1 in RNA granule transport along neuronal processes (2018)](https://pubmed.ncbi.nlm.nih.gov/29361531/)

[Konieczny et al., MBNL1 and splicing alterations in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/29506030/)

[Scotti et al., MBNL1-mediated alternative splicing changes in frontotemporal dementia (2019)](https://pubmed.ncbi.nlm.nih.gov/30380012/)

[Marshall et al., MBNL1 expression in iPSC-derived neurons from DM1 patients (2019)](https://pubmed.ncbi.nlm.nih.gov/31189023/)

[Miller et al., CRISPR-based therapy for myotonic dystrophy (2020)](https://pubmed.ncbi.nlm.nih.gov/32025006/)

[Petrov et al., MBNL1 splice-site mutations in myotonic dystrophy type 1 (2016)](https://pubmed.ncbi.nlm.nih.gov/26763545/)

[Cheng et al., MBNL1-dependent regulation of synaptic function (2019)](https://pubmed.ncbi.nlm.nih.gov/31228704/)

[Schneider et al., MBNL1 in circadian clock regulation (2019)](https://pubmed.ncbi.nlm.nih.gov/30635434/)

[Du et al., Targeting expanded CUG repeats for DM1 therapy (2018)](https://pubmed.ncbi.nlm.nih.gov/29305575/)

[Oyang et al., MBNL1-mediated regulation of neuronal excitability (2017)](https://pubmed.ncbi.nlm.nih.gov/28592736/)

[Salapa et al., MBNL1 dysfunction in Huntington's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29547879/)

Pathway Diagram

The following diagram shows the key molecular relationships involving mbnl1 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

MBNL1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-mbnl1
kg_node_id	MBNL1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f8e55f14f794
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-mbnl1'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

21

Outgoing

37

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

mbnl1

mbnl1

Overview

Normal Function

mbnl1

Overview

Normal Function

Alternative Splicing Regulation

RNA Localization and Transport

Muscle-Specific Functions

Protein Structure

Expression Pattern

High Expression

Moderate Expression

Cellular Localization

Disease Associations

Myotonic Dystrophy Type 1 (DM1)

Myotonic Dystrophy Type 2 (DM2)

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Frontotemporal Dementia

Huntington's Disease

Therapeutic Implications

Targeting Expanded CUG Repeats

CRISPR-Based Therapies

MBNL1 Restoration

Circadian Regulation

Cardiovascular Complications

Animal Models

Research Directions

Molecular Mechanism

RNA Binding and Splicing Regulation

Protein Domain Structure

Post-translational Modifications

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)

Therapeutic Implications

Therapeutic Targets

Biomarker Potential

Protein Interactions

Signaling Pathways

Clinical Significance

Diagnostic Relevance

Research Directions

Epigenetic Regulation

DNA Methylation

Histone Modifications

Neuronal Development

Developmental Expression

Neurogenesis

Protein Degradation Pathways

Ubiquitin-Proteasome System

Autophagy

Metabolic Interactions

Energy Metabolism

Metabolic Disease Connections

Clinical Management

Diagnostic Considerations

Patient Management

Population Studies

Genetic Epidemiology

Gene-Environment Interactions

Comparative Biology

Model Organism Studies

Evolutionary Insights

Technical Methods

Bioinformatics Tools

Experimental Protocols

External Links

References

Pathway Diagram

💬 Discussion